BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29 | -95.0% | 145,500 | -48.0% | 0.00% | -95.3% |
| Q2 2023 | $577 | -37.6% | 280,000 | 0.0% | 0.08% | -39.3% |
| Q1 2023 | $924 | +101.3% | 280,000 | 0.0% | 0.14% | +97.2% |
| Q4 2022 | $459 | -100.0% | 280,000 | 0.0% | 0.07% | -68.7% |
| Q3 2022 | $1,238,000 | +69.4% | 280,000 | +5.7% | 0.23% | +80.2% |
| Q2 2022 | $731,000 | -17.9% | 265,000 | 0.0% | 0.13% | +0.8% |
| Q1 2022 | $890,000 | -4.5% | 265,000 | +13.7% | 0.12% | +3.3% |
| Q4 2021 | $932,000 | +37.9% | 233,000 | +13.7% | 0.12% | +27.4% |
| Q3 2021 | $676,000 | -26.4% | 205,000 | -15.1% | 0.10% | -25.8% |
| Q2 2021 | $918,000 | -0.8% | 241,500 | 0.0% | 0.13% | -8.6% |
| Q1 2021 | $925,000 | -15.4% | 241,500 | 0.0% | 0.14% | -17.6% |
| Q4 2020 | $1,093,000 | -73.1% | 241,500 | +0.4% | 0.17% | -75.2% |
| Q3 2020 | $4,069,000 | +51.9% | 240,500 | +0.6% | 0.69% | +42.6% |
| Q2 2020 | $2,679,000 | +930.4% | 239,000 | +326.4% | 0.48% | +715.3% |
| Q1 2020 | $260,000 | – | 56,050 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |